Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Targeted Anticancer Therapies Congress 2025

Workshop in collaboration with ESMO YOC: Evaluation of phase I data at the end of the study for next planning of drug development

Early evaluation of efficacy in phase I trials: Persevere or halt the programme?

Date

05 Mar 2025

Session

Workshop in collaboration with ESMO YOC: Evaluation of phase I data at the end of the study for next planning of drug development

Topics

Clinical Research;  Response Evaluation (RECIST Criteria);  Therapy

Tumour Site

Presenters

Jordi Rodon

Authors

J. Rodon

Author affiliations

  • Drug Development Department, The University of Texas MD Anderson Cancer Center - Main Building, 77030 - Houston/US

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Q&A and discussion

Session: Workshop in collaboration with ESMO YOC: Evaluation of phase I data at the end of the study for next planning of drug development

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.